Jun 10th, 2021
Society of Family Planning Research Fund Grant Announcement
May 3rd, 2021
Gynuity shares research and programmatic updates in maternal health
Mar 29th, 2021
Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic
Jan 26th, 2021
Feasibility of Multilevel Pregnancy Tests for Telemedicine Abortion Service Follow-up: A Pilot Study
Jan 22nd, 2021
Missed Period Pills in the News
Jan 12th, 2021
The Safety and Feasibility of a Family First Aid Approach for the Management of Postpartum Hemorrhage in Home Births: A Pre‑post Intervention Study in Rural Pakistan
Dec 4th, 2020
New York Times article: Why Some Women Might Want 'Missed-Period Pills'
Dec 2nd, 2020
¡Todavía hay cupos! Regístrese para el curso que comienza el 3 de diciembre de 2020
Nov 24th, 2020
Newsletter November 2020
Oct 30th, 2020
Exploring Potential Interest in Missed Period Pills in two US States
Sep 21st, 2020
Gynuity Staff Awarded Two Daniel R. Mishell Jr., MD, Outstanding Article Awards
Aug 31st, 2020
New Resources and Articles from Gynuity
Jul 22nd, 2020
A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review
Jun 22nd, 2020
Gynuity’s Recent Articles on Management of Postpartum Hemorrhage
Jun 17th, 2020
Multi-level pregnancy test use for medical abortion follow-up after 63 days’ gestation: Evidence from prenatal hCG data
May 25th, 2020
Annual Gynuity Mifepristone Meeting
May 19th, 2020
TelAbortion Media Toolkit
Apr 28th, 2020
New York Times article: Abortion by Telemedicine: A Growing Option as Access to Clinics Wanes
Apr 14th, 2020
No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond
Apr 9th, 2020
COVID-19
Mar 18th, 2020
Learn About Our Latest Endeavors and Publications
Mar 16th, 2020
A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation
Sensitivity and specificity of placental proteins for gestational age screening: An exploratory study
A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries
